|
|
Article: CSL Biotherapies, a New Entrant Into U.S. Flu Market, Starts Influenza Vaccine Biological Licensure Trial.
- Article from:
- PR Newswire
- Article date:
- June 5, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Enrollment Starts for NIH-Sponsored Study
KING OF PRUSSIA, Pa., June 5 /PRNewswire/ -- Enrollment will begin for a pivotal influenza vaccine clinical trial sponsored by the National Institutes of Health (NIH), CSL Biotherapies announced today. The study will assess the safety and immunogenicity of single-dose and multi-dose formulations of influenza vaccine and has been designed to meet U.S. Food & Drug Administration (FDA) requirements.
CSL Biotherapies will supply the vaccine, which is already approved and widely supplied in 16 countries throughout the world. CSL Biotherapies' parent company, CSL Limited, has partnered with the National Institute of ...
Related newspaper, magazine, and journal articles:
|
|
Article: CSL Biotherapies Contracts with U.S. Department of ...
Vaccine Weekly;
June 17, 2009 ;
700+ words
... ... difference." CSL Biotherapies' Novel A (H1N1 ... influenza strain. CSL Limited, parent company to CSL Biotherapies, is currently ... headquarters of CSL Biotherapies are located in ... parent company, CSL Limited, in Melbourne ...
|
|